A B S T R A C T We report
INTRODUCTION
Methylmalonic aciduria has been observed in patients whose tissues are low in methylmalonyl CoA mutase (E.C. 5.4.99.2) activity (1) (2) (3) (4) (5) (6) (7) (8) , and in organisms rendered deficient in vitamin Bu (9) (10) (11) (12) . During these states, there is a tendency for hypoglycemia and ketoacidosis, which is exacerbated after the administration of propionate or one of its precursors (1) .
Increased hepatic concentrations of methylmalonyl CoA (MMCoA)1 could inhibit gluconeogenesis by de- creasing pyruvate carboxylase activity (13) (Scheme 1). Utter and coworkers (13) have demonstrated that acetyl Received for publication 2 April 1971 and in revised form 14 June 1971. 'Abbreviations used in this paper: MMA, methylmalonic acid; MMCoA, methylmalonyl coenzyme A; EGTA, ethylene glycol bis(,f-aminoethyl ether)-tetraacetic acid; FC- CP, carbonyl-cyanide-p-trifluoro-methoxyphenyl hydrazine.
CoA or propionyl CoA is required for activation of the enzyme which catalyzes the conversion of pyruvate to oxaloacetate. In contrast, malonyl CoA and MMCoA competitively inhibit this activation (13) . Since hepatic concentrations of MMCoA have not yet been measured, the physiological significance of the inhibition of pyruvate carboxylase by MMCoA cannot be directly assessed. The high K'i for MMCoA (0.43 mM) in the pyruvate carboxylase reaction, and the relatively low K'1 for acetyl CoA and propionyl CoA (< 50 F'M and 100 AM, respectively, at physiological pH [13] ) do not favor the likelihood of a simple control of the pyruvate carboxylase reaction by these competitive intermediates.
An alternate site for regulation of gluconeogenesis is the transport of malate from mitochondria to the cytoplasmic compartment (14, 15) . Butylmalonate, an inhibitor of the malate-phosphate exchange reaction across the mitochondrial membranes (16) , has recently been shown to inhibit gluconeogenesis from pyruvate in perfused livers (17) . It appeared possible that methylmalonate, which accumulates when MMCoA cannot be readily converted to succinyl CoA, might inhibit malate transport across mitochondrial membranes, just as do other malonate *derivatives such as butylmalonate (16) and pentylmalonate (18) .
In this report, we show that methylmalonic acid (MMA) does inhibit the transport of L-malate across rat liver mitochondrial membranes, and that MMA itself may be transported by all of the three carrier systems for malate previously detailed by Robinson 
RESULTS
Low concentrations of isocitrate or oxoglutarate do not increase mitochondrial oxygen consumption significantly unless L-malate is present (Fig. 1A) (14) . With isocitrate or oxoglutarate as substrates, addition of MMA was able to substitute partially for malate (Fig. 1B) .
MMA did not inhibit the malate-induced stimulation of oxygen consumption by mitochondria incubated with isocitrate ( Fig. 1A) . In contrast, MMA inhibited the rate of malafe-stimulated respiration of mitochondria incubated with oxoglutarate. This inhibition (Fig. 1A) may be analogous to the well-known inhibition of succinic dehydrogenase activity by malonate. Data in Fig.  1 cubated with rotenone to inhibit oxidation, were suspended in isosmotic ammonium salts of either fumarate (curve 1 of Fig. 2 ), malate (curve 2 of Fig. 2 ), or malate plus fumarate (curve 3 of Fig. 2 ). Under these Malate P. conditions, the rate of mitochondrial swelling is dependent on penetration of an anion associated with the addition of inorganic phosphate (22) . With malate as the anion, the swelling rate was equally rapid at concentrations of 50 or 100 mm (Fig. 2) . In contrast, with fumarate as the anion, swelling was inappreciable (curve 1 of Fig. 2 ). These data confirm previous observations by others (22) . With MMA as the anion, swelling occurred at a slower rate than in the presence of malate (curve 4 of Fig. 2) , suggesting a slower rate of mitochondrial penetration of MMA than of malate on the dicarboxylate carrier. The combination of 50 mm MMA and 50 mm malate (curve 5 of Fig. 2 ) resulted in a significantly slower rate of phosphate-induced swelling than that seen with 100 mM L-malate, or with the combination of 50 mM L-malate and 50 mm fumarate. These data indicate that MMA inhibited the malate-phosphate exchange when MMA was present at a concentration equal to that of malate, even though both MMA and L-malate are substrates for the same transport system.
When rat liver mitochondrial NAD (P) redox changes were followed by fluorimetry (23), a rapid oxidation occurred after the addition of the uncoupling agent FCCP (Fig. 3) . After addition of the respiratory inhibitor antimycin A, L-malate alone caused a small reduction of NAD (P) (Fig. 3A) . After either isocitrate or oxoglutarate was added to the system under these conditions, rapid reduction of intramitochondrial NAD (P) occurred (Fig. 3A) occurred until malate was added (Fig. 3A) . These findings confirm the requirement for a dicarboxylate anion as an activator of the tricarboxylate or oxoglutarate transporting system (14) . In the absence of isocitrate or oxoglutarate, addition of MMA had no effect on the redox potential (Fig. 3B) . Other data presented in Fig. 3B demonstrate that MMA could substitute for L-malate as an activator of the tricarboxylate or oxoglutarate transport systems. The stimulation of isocitrate oxidation by MMA could be prevented by incubation of mitochondria with pentylmalonate before the addition of MMA. Pentylmalonate inhibited the MMA effect by blocking MMA entry into mitochondria on the dicarboxylate carrier (data not shown).
As indicated in experiments depicted in Fig. 3A , the addition of 0.25 mM L-malate alone rapidly increased the steady state concentration of NAD(P)R to a small extent. This reduction was inhibited by MMA (Fig. 4) . The rapid and nearly complete reduction of NAD(P)H Pi I I' Swelling 60 sec FIGURE 2 Swelling of rat liver mitochondria in isosmotic ammonium malate, fumarate, or MMA. Liver mitochondria (1-2 mg protein) were suspended in 1.0 ml of medium containing 100 mM ammonium malate, fumarate or MMA, or 50 mm concentrations of each of two of these substrates. The medium also contained 10 mm Tris-HCl, pH 7.4, 1 mm EGTA, and 0.5 ,ug/ml rotenone. Addition of ammonium phosphate (Pi) was made at the indicated time to give a final concentration of 2.0 mm. Swelling was followed by recording changes in absorbance at 578 nm of the mitochondrial suspension in a 1 cm light path cell. In curve 1, 100 mm ammonium fumarate was present; in curve 2, 100 mm ammonium malate was present; in curve 3, 50 mm ammonium fumarate and 50 mm ammonium malate were present; in curve 4, 100 mm ammonium MMA was present; and in curve 5, 50 mm ammonium MMA and 50 mM ammonium malate were present in the incubation medium. T Percentage exchange was calculated as follows:
Corrected counts per minute in supernatant fraction Total counts per minute in supernatant plus pellet ) 100.
which ordinarily followed isocitrate addition in the presence of L-malate was also decreased by MMA (Fig. 4) , with a greater inhibition obtained with 5 mm MMA than with 2.5 mm MMA (compare curves 2 and 3 with curve 1 of Fig. 4 ). The effects of MMA on citrate-14C exchange in mitochondria incubated with antimycin A and rotenone are summarized in Table I . These data demonstrate that MMA exchanged for citrate at a rate which was 40% of that observed with malate. Since the exchange occurred in mitochondria whose respiration was inhibited, it may be concluded that MMA increased citrate transport independent of oxidation. It should be noted that MMA and malate are both substrates for the tricarboxylate carrier, and that MMA does not inhibit this transporter (Fig. 1) . The additive effects of nonsaturating concentrations of the two compounds on the exit of citrate and isocitrate from preloaded mitochondria (Table I) corroborated these results.
DISCUSSION
Data presented in Fig. 2 demonstrate that malate transport into mitochondria was inhibited by MMA, and this most probably accounts for the inhibition of malate oxi- dation by MMA depicted in Fig. 4 . We assume that these findings on malatae entry are applicable to malate efflux from mitochondria, since it appears likely that the carrier properties for anion transporters are similar on both sides of the mitochondrial membrane. When we measured the efflux of L-malate-14C previously loaded into mitochondria, we were unable to obtain an inhibition by MMA (data not shown). This result was anticipated because malate exchange with MMA occurs on both the tricarboxylate and oxyglutarate carriers, neither of which is inhibited by MMA (Scheme 2). Thus, even though the dicarboxylate carrier was inhibited by MMA (Fig. 2) , the exit of L-malate-'4C readily occurred via the remaining carrier systems. In order to test the effects of MMA on malate exit via the dicarboxylate carrier from preloaded mitochondria, it would be necessary to use other inhibitors which specifically blocked only the tricarboxylate and oxyglutarate transport systems. Although a suitable inhibitor exists (1,2,3-benzene tricarboxylate) for the tricarboxylate carrier (19) , none is available for the oxyglutarate carrier at this time.
The observed inhibition by MMA of the mitochondrial dicarboxylate transport system could partially account for the hypoglycemia associated with patients having methylmalonic aciduria. As indicated in Scheme 1, regulatory reactions for gluconeogenesis which could be inhibited by MMA or methylmalonyl CoA include several of the steps responsible for the conversion of intramitochondrial substrates to extramitochondrial oxaloacetate, leading to the generation of phosphoenolpyruvate and hence to glucose. propionate to malate bypasses the pyruvate carboxylase reaction, but it remains possible that MMA could have inhibited gluconeogenesis either by blocking succinic dehydrogenase, malate exit, or both (Scheme 1). Assuming that similar effects are obtained in liver (17) as in kidney (24), it follows that accumulation of MMA in patients having methylmalonic aciduria would inhibit gluconeogenesis by inhibiting reactions shown in Scheme 1. The plasma concentration of MMA in patients is around 1-2 mm (1, 6), and it could reasonably be expected to be appreciably higher within liver cells of patients lacking MMCoA mutase atcivity. From data presented in the Results section, it appears that these levels of MMA would inhibit the malate transport system. In patients with hypoglycemia, ketonemia, and methylmalonic aciduria, it may be predicted from data presented in Figs. 1-3 that treatment with sodium citrate plus glucose may be more beneficial than glucose alone. The citrate would enter liver mitochondria in exchange for MMA, thus allowing a more rapid escape of MMA from the mitochondria. The increased MMA levels in the cytosol would facilitate more rapid diffusion to the extracellular space and eventual excretion in the urine. This should permit a faster restoration of normal hepatic levels of MMA and MMCoA, thereby relieving the inhibition of malate exist and gluconeogenesis.
